GNRH1 and adenomyosis: The presence of anti-proliferative, hypoestrogenic effects resulting from the administration of GnRH agonists is thought to be involved in the regression of adenomyosis in reducing the size of the uterus thereby suppressing the symptoms of adenomyosis [14].